Skip to main content

Table 2 Univariate analysis

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

 

Non-rituximab-RIC

N = 1022

Rituximab-containing RIC

N = 379

 

Outcomes

N eval

Prob (95%CI)

N eval

Prob (95%CI)

p value

ANC recovery >500/uL

1013

 

379

  

 28 days

 

97 (96–98)%

 

98 (96–99)%

0.51

 100 days

 

99 (98–99)%

 

99 (97–100)%

0.99

Platelet recovery ≥ 20/uL

986

 

378

  

 28 days

 

90 (88–92)%

 

90 (87–93)%

0.66

 100 days

 

96 (94–97)%

 

96 (93–97)%

0.79

Acute GVHD (II IV)

1004

 

377

  

 180 days

 

37 (34–40)%

 

43 (38–48)%

0.03

Acute GVHD (III IV)

1004

 

377

  

 180 days

 

13 (11–16)%

 

16 (12–19)%

0.29

Chronic GVHD

982

 

369

  

 1 year

 

44 (41–48)%

 

41 (36–47)%

0.32

 2 years

 

53 (50–57)%

 

53 (47–58)%

0.79

NRM

988

 

367

  

 1 year

 

14 (12–16)%

 

13 (10–17)%

0.78

 3 years

 

21 (18–24)%

 

20 (16–24)%

0.68

Relapse/progression

988

 

367

  

 1 year

 

26 (23–29)%

 

19 (15–23)%

0.004

 3 years

 

32 (29–35)%

 

24 (20–29)%

0.005

PFS

988

 

367

  

 1 year

 

60 (57–63)%

 

68 (63–72)%

0.007

 3 years

 

47 (44–50)%

 

56 (51–61)%

0.005

Mortality (inverse of OS)

1022

 

379

  

 1 year

 

70 (67–73)%

 

76 (71–80)%

0.04

 3 years

 

56 (53–59)%

 

64 (59–68)%

0.01

  1. Probabilities of neutrophil and platelet recovery, platelet recovery, acute GVHD, chronic GVHD, treatment-related mortality, and progression/relapse were calculated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimate
  2. Abbreviations: ANC absolute neutrophil count, GVHD graft-versus-host disease, PROB probability, CI confidence interval, N eval number evaluable, NRM non-relapse mortality, PFS progression free survival, RIC reduced-intensity conditioning, OS overall survival